+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Bronchitis Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4896185
  • Report
  • June 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence
1 of 5


  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Melinta Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A
  • MORE
The bronchitis treatment market studied was anticipated to grow with a CAGR of 3.6% over the forecast period. The major factor attributing to the growth of the bronchitis treatment market is a large patient pool with COPD diseases. According to CDC (Centres for Disease Control and Prevention) in 2018, 9.0 million adults got diagnosed with chronic bronchitis and there are few more factors which are playing pivotal roles in taking the bronchitis treatment market to the next level such as an increase in geriatric population with increased prevalence of bronchitis, rise in habits like smoking and increased levels of chemical pollutants.

According to the recent report from COPD foundation.org smoking is associated with 90 percent of all COPD deaths in the United States. Thus, all of the above mentioned factors are expected to drive the growth of the market.

Key Market Trends

Bronchodilators is the Expected to Show a High Growth During the Forecast Period

Bronchodilators are drugs that open the airway passages and are also used for expanding the windpipe, thus improving the breathing of the individuals suffering from lung infections, bronchial asthma, and chronic obstructive pulmonary disease (COPD). Bronchodilators are the first-line medication for the treatment of bronchitis for clearing the airway obstruction, which is an essential thing in chronic bronchitis to ease the breathing of the patient.

The major factors, such as increasing incidence of respiratory diseases and the rising prevalence of smoking, are driving the growth of the market segment. Therefore, as the number of respiratory diseases is increasing, there is a demand for bronchodilators.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall bronchitis treatment market throughout the forecast period. This is due to factors such as the rising incidence of bronchitis and an increasing trend of smoking in the young generation.

In the North America region, the United States holds the largest market share due to factors such as a growing number of geriatric populations, along with an increasing number of diseases in the country, well-established insurance policies and the availability of advanced healthcare infrastructure are few of the major factors, which is anticipated to stimulate the demand in this region. According to the Centers for Disease Control and Prevention (CDC), 9.0 million adults were diagnosed with Chronic bronchitis in the United States for the year 2017, and the incidence of the disease is rising which further increases the market growth.

Competitive Landscape

The bronchitis treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Melinta Therapeutics, Sanofi S.A, and Boehringer Ingelheim International GmbH, and Pfizer Inc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 5


  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Melinta Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Geriatric Population with Increased Incidence of Bronchitis
4.2.2 Increased Prevalence of COPD Cases
4.2.3 Increased Smoking and Rising Levels of Chemical Pollutants
4.3 Market Restraints
4.3.1 Patent Expiry of Key Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Class of Drugs
5.1.1 Antibiotics
5.1.2 Anti-inflammatory Drugs
5.1.3 Bronchodilator
5.1.4 Other
5.2 By End User
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Other
5.3 By Type
5.3.1 Acute Bronchitis
5.3.2 Chronic Bronchitis
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AstraZeneca plc
6.1.2 Novartis AG
6.1.3 GlaxoSmithKline plc
6.1.4 Dr. Reddy's Laboratories Ltd.
6.1.5 Sanofi S.A
6.1.6 Boehringer Ingelheim International GmbH
6.1.7 Pfizer Inc.
6.1.8 Melinta Therapeutics

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • AstraZeneca plc
  • Novartis AG
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Sanofi S.A
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Melinta Therapeutics
Note: Product cover images may vary from those shown
5 of 5